Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
600
¥100 million (full-year revenue forecast revision)Wording
Definitive
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFY2026 second quarter8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥11,672 hundred million+19.7%
Operating profit¥1,938 hundred million+34.4%
Ordinary income¥1,929 100 million +18.2%profit before tax
Net income¥1,515 100 million +15.8%attributable to owners of the parent
Operating profit margin16.6 %
Selling, general and administrative expenses¥4,661 hundred million
Results for the three months of the current quarter
Revenue
¥5,925 hundred million
Operating profit
¥1,087 hundred million
Profit attributable to owners of the parent
¥829 hundred million
Full-year earnings forecast
Revenue
¥23,400 hundred million
Cost of sales
¥5,500 hundred million
Gross profit
¥17,900 hundred million
Selling, general and administrative expenses
¥9,300 hundred million
R&D expenses
¥5,000 hundred million
Core operating profit
¥3,600 hundred million
Operating profit
¥3,200 hundred million
Pretax profit
¥3,340 hundred million
Profit for the period
¥2,540 hundred million
Profit attributable to owners of the parent
¥2,510 hundred million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Revenue49.9 %
Cost of sales43.6 %
Gross profit51.8 %
Selling, general and administrative expenses50.1 %
R&D expenses48 %
Core operating profit61.5 %
Operating profit60.6 %
Pretax profit57.7 %
Profit for the period60.3 %
Profit attributable to owners of the parent60.4 %
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue
Foreign Exchange Effects
¥739 hundred million
Operating profit
Foreign Exchange Effects
¥316 hundred million
Pretax profit
Deterioration in securities valuation gains/losses
¥-5 hundred million
Increase in interest expense
¥-23 hundred million
Decline in dividend income
¥-13 hundred million
Deterioration in foreign exchange gains/losses
¥-140 hundred million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Assumed exchange rate from the third quarter onward
USD/yen155
EUR/yen180
Revised forecast exchange rate
USD/yen157.19
EUR/yen182.18
Key KPIsA metric the company considers important as a management benchmark.
- Overseas Revenue Mix75.5 %Year on year against the same period last year+5.6%
- Trastuzumab deruxtecan revenue¥5,000 hundred millionYear on year against the same period last year+51.4%
- Datopotamab deruxtecan revenue¥544 hundred millionYear on year against the same period last year+161.6%
- Edoxaban revenue¥1,812 hundred millionYear on year against the same period last year-2.6%
Segment results
Japan Business Unit
Sales
¥2,327 hundred million-6.9%
Daiichi Sankyo Healthcare Unit
Sales
¥483 hundred million+5.1%
Oncology Business Unit
Sales
¥4,226 hundred million+54.8%
American Regent Unit
Sales
¥779 hundred million-19.5%
EU Specialty Business Unit
Sales
¥1,492 hundred million+9.1%
ASCA Business Unit
Sales
¥1,425 hundred million+20.9%
Number of employees
Number of Employees20,053 people
Change during the period-118 people
Capital expenditures
¥666 billion cumulative results for the second quarter
Acquisition of treasury shares
Acquisition amount¥5 hundred million
Gross profit
79.5 %
yoy_change_pt4
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | FY2026 second quarter |
| Net Sales | ¥11,672 hundred million (YoY +19.7%) |
| Operating profit | ¥1,938 hundred million (YoY +34.4%) |
| Ordinary income | ¥1,929 100 million (profit before tax) (YoY +18.2%) |
| Net income | ¥1,515 100 million (attributable to owners of the parent) (YoY +15.8%) |
| Gross profit | 79.5 % |
| Operating profit margin | 16.6 % |
| Selling, general and administrative expenses | ¥4,661 hundred million |
| Results for the three months of the current quarter | Revenue ¥5,925 hundred million / Operating profit ¥1,087 hundred million / Profit attributable to owners of the parent ¥829 hundred million |
| Full-year earnings forecast | Revenue ¥23,400 hundred million / Cost of sales ¥5,500 hundred million / Gross profit ¥17,900 hundred million / Selling, general and administrative expenses ¥9,300 hundred million / R&D expenses ¥5,000 hundred million / Core operating profit ¥3,600 hundred million / Operating profit ¥3,200 hundred million / Pretax profit ¥3,340 hundred million / Profit for the period ¥2,540 hundred million / Profit attributable to owners of the parent ¥2,510 hundred million |
| Progress against full-year forecast | Revenue 49.9 % / Cost of sales 43.6 % / Gross profit 51.8 % / Selling, general and administrative expenses 50.1 % / R&D expenses 48 % / Core operating profit 61.5 % / Operating profit 60.6 % / Pretax profit 57.7 % / Profit for the period 60.3 % / Profit attributable to owners of the parent 60.4 % |
| Segment results | Japan Business Unit Sales ¥2,327 hundred million (YoY -6.9%) / Daiichi Sankyo Healthcare Unit Sales ¥483 hundred million (YoY +5.1%) / Oncology Business Unit Sales ¥4,226 hundred million (YoY +54.8%) / American Regent Unit Sales ¥779 hundred million (YoY -19.5%) / EU Specialty Business Unit Sales ¥1,492 hundred million (YoY +9.1%) / ASCA Business Unit Sales ¥1,425 hundred million (YoY +20.9%) |
| Breakdown of Factors Affecting the Change | Revenue Foreign Exchange Effects ¥739 hundred million / Operating profit Foreign Exchange Effects ¥316 hundred million / Pretax profit Deterioration in securities valuation gains/losses ¥-5 hundred million / Increase in interest expense ¥-23 hundred million / Decline in dividend income ¥-13 hundred million / Deterioration in foreign exchange gains/losses ¥-140 hundred million |
| Key KPIs | Indicator name Overseas Revenue Mix / Value 75.5 % / Year on year against the same period last year 5.6 %, Indicator name Trastuzumab deruxtecan revenue / Value ¥5,000 hundred million / Year on year against the same period last year ¥51.4 hundred million, Indicator name Datopotamab deruxtecan revenue / Value ¥544 hundred million / Year on year against the same period last year ¥161.6 hundred million, Indicator name Edoxaban revenue / Value ¥1,812 hundred million / Year on year against the same period last year ¥-2.6 hundred million |
| Number of employees | Number of Employees 20,053 people / Change during the period -118 people |
| Assumptions Underlying the Business Outlook | Assumed exchange rate from the third quarter onward USD/yen 155 / EUR/yen 180 / Revised forecast exchange rate USD/yen 157.19 / EUR/yen 182.18 |
| Acquisition of treasury shares | Acquisition amount ¥5 hundred million |
| Capital expenditures | ¥666 billion (cumulative results for the second quarter) |
Items this document does not state (12)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue was driven in part by a ¥73.9 billion foreign exchange impact. Operating profit benefited from higher gross profit, but profit sharing for DXd ADC products, other selling, general and administrative expenses, and research and development expenses increased. The full-year forecast for profit attributable to owners of the parent was lowered due to an increase in income taxes and other taxes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.